Incidence of Invasive Aspergillosis and Its Relation to Galactomannan Clinical Outcomes

The goal of this observational study is to analyze the relationship between galactomannan index values and clinical outcomes , as well as to determine the annual and seasonal incidence of invasive aspergillosis in pediatric and adult patients with suspected or confirmed infection at Hospital H+ Querétaro.

The main questions it aims to answer are:

* Are high galactomannan levels significantly associated with adverse clinical outcomes, such as mortality and longer hospital stays, in immunocompromised patients? * How does the incidence of invasive aspergillosis vary annually and seasonally between March 2022 and March 2026? Researchers will compare patients with high galactomannan levels against those with low or negative levels to see if this biomarker can be used as a reliable tool to predict patient outcomes.

The research team will:

* Collect and review clinical files of patients who had a galactomannan test from bronchoalveolar lavage samples. * Record data on galactomannan levels, hospital stays, and patient recovery or complications.Identify risk factors and seasonal patterns of the infection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Invasive Aspergillosis

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital H+

Querétaro City, Querétaro, 7600, Mexico

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who underwent galactomannan determination testing in bronchoalveolar lavage (BAL) samples
Tests performed during the period from March 2022 to March 2026.

Exclusion criteria

Patients with galactomannan tests performed outside the established period (March 2022 to March 2026).
Galactomannan tests performed using serum samples.

Treatment and study plan

Primary outcomes

Incidence of Invasive Aspergillosis and Association of Galactomannan Index with Clinical Outcomes

Time frame: From March 2022 to March 2026

An analysis to determine the annual and seasonal incidence of Invasive Aspergillosis (IA) , alongside a quantitative evaluation of how Galactomannan (GM) index values relate to clinical outcomes in patients. The study will measure the association of GM levels with specific adverse endpoints, including patient mortality, length of hospital stay (estancia hospitalaria), intensive care unit (ICU) admission, and the development of clinical complications. Additionally, it will compare these clinical outcomes between patients with elevated GM levels against those with low or negative levels to evaluate GM's utility as a prognostic marker.

Sponsors and collaborators

Lead sponsor

Hospital H+ Queretaro

Other

Registry information

Official study title

Incidence of Invasive Aspergillosis at Hospital H+ Querétaro and the Relationship Between Galactomannan and Clinical Outcomes

Important dates

Study start: 2022
Primary completion: 2026
Study completion: 2026
First posted: Jun 2, 2026
Registry last updated: Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed